Angehängte Grafik: immunocore_pipeline_bei_ipo_07.png (verkleinert auf 54%)
: Trotz aller allgemeinen Widrigkeiten sehr guter
Zeitpunkt für den Börsengang gewählt - am zweiten Tag +30,42% ist schon erstaunlich. Mal sehen ob die Ernüchterung und der Ausverkauf kommt, oder ob das Interesse ungebrochen ist. Sie wären vermutlich gut beraten bald auch in UK an die Börse zu gehen und haben im Augenblick noch den grossen Vorteil 1:1 im Aktienverhältnis US - UK zu sein, was bei der Schwesterfirma Adaptimmune mit einem 1:6 Verhältnis immer zu Fehleinschätzungen und Falschdarstellungen für Aktienanteile und deren Werthaltigkeit führt.
At the 2021 virtual AACR conference, Jessica Hassel, Associate Professor at the National Center for Tumor Diseases, University Hospital, Heidelberg, presented impressive Phase 3 results of Immunocores? bispecific antibody tebentafusp in treating metastatic uveal melanoma.
Immunocore presents phase 3 data comparing tebentafusp with investigator?s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting 12 April 2021 at 4:30 PM EDT Download PDF PRESS RELEASE
Immunocore presents phase 3 data comparing tebentafusp with investigator?s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting
"Tebentafusp is the first investigational therapy to improve Overall Survival (OS) in patients with metastatic uveal melanoma
First positive Phase 3 clinical trial for any T cell receptor therapeutic and first for any bispecific in a solid tumor
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 12 April 2021) Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, presented data from a phase 3 randomized trial comparing tebentafusp (IMCgp100) with investigator?s choice in first-line metastatic uveal melanoma (mUM) in the clinical trial plenary session at the American Association for Cancer Research (AACR) Annual Meeting 2021.
Tebentafusp demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) as a first-line treatment in mUM. The OS Hazard Ratio (HR) in the intent-to-treat population favored tebentafusp, HR=0.51 (95% CI: 0.37, 0.71); p< 0.0001, over investigator?s choice (82% pembrolizumab; 12% ipilimumab; 6% dacarbazine). Treatment-related adverse events were manageable and consistent with the proposed mechanism..." https://ir.immunocore.com/news-releases/...data-comparing-tebentafusp
wie Immunocore schon in der Pressemitteilung zum letzten Quartalsbericht und ausführlicher im Jahresbericht Seite 127 beschrieben hatte: "Under the GSK Agreement, we granted GSK the right to nominate up to four targets as being exclusive to GSK under our collaboration. The first target, GSK01/NY-ESO, was nominated at the time of execution of the GSK Agreement. A second target was nominated in July 2017. GSK has no further ability to nominate additional targets under the GSK Agreement. Under the GSK Agreement, for NY-ESO, we are responsible for the development of the soluble TCR bispecific therapeutic candidate compounds through initial Phase 1 clinical trials. The GSK-01 NY-ESO Phase 1 dose escalation study to determine safety, and which is enrolling several different tumor types, is still ongoing. An expansion phase was planned to initiate once the Phase 1 dose escalation was complete. However, following a portfolio review, we, in collaboration with GSK, have jointly elected not to plan for or initiate the efficacy determining expansion phase. The expansion arm was planned to be conducted in synovial sarcoma, an ultra-rare disease which is already addressed by other assets in our portfolio including MAGE-A4 and PRAME. Consequently, GSK has forgone their option to acquire an exclusive license to the NY-ESO program and we will retain ownership of the asset. We will present the data from this Phase 1 study in 2022."